Welcome to PsychU!

Effectiveness Of Interventions To Improve Medication Adherence In Bipolar Disorder

Key Messages

The World Health Organization (WHO) has reported that 50% of patients from developed countries with chronic disease do not use their medications as recommended.
In bipolar disorder (BD) non-adherence to medication has been associated with a range of poor clinical outcomes including higher rates of hospital admission, higher rates of suicide, and recurrence of acute episodes, particularly mania.
Rates of relapse in BD have been reported to be as high as 40% in the first year, 60% in the second year, …

Join PsychU today at no cost for access to this and other premium content!

Join today for instant access to all PsychU content, events, and more!

Membership is free!

Name*
Specialty*
Zip / Postal Code*

Choose Your Unique Login

Your username can only contain lowercase letters (a-z) and numbers.
Email*
Password*
Your password must be at least 8 characters Hint: Must use combination of lower case letters, upper case letters, numbers and special characters like !@#$.

I AGREE TO THE FOLLOWING TERMS

I agree to the following terms:*
I agree to the following terms*
Hidden
Direct Care Provider
Hidden
Clinician Newsletter
Hidden
Management Newsletter
Hidden
user_preferences_account_notifications
Hidden
user_preferences_webinar_emails

Event Registration

MM slash DD slash YYYY
Hidden
Hidden

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS

PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.

PSYCHU MEMBERSHIP ELIGIBILITY

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients. NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.

MEMBERSHIP & REGISTRATION

Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.

ATTENDANCE LIMITATIONS

PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.

MEAL REPORTING

The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Hidden
Hidden
This field is for validation purposes and should be left unchanged.

Background & Purpose

The following is a summary of Crowe M. et al. Effectiveness of interventions to improve medication adherence in bipolar disorder. Australian & New Zealand Journal of Psychiatry 46(4) 317–326.

  • In BD non-adherence to medication has been associated with a range of poor clinical outcomes that included higher rates of hospital admissions, suicide, and recurrent of acute episodes, particularly mania. Numerous interventions have been studied in an attempt to improve mediation adherence in long-term conditions; however, it was found that less than half the interventions tested were associated with statistically increased medication adherence. The objective of this review was to identify which interventions enhanced medication adherence in BD, from the published literature of controlled trials between 2003 and 2011.
    • This review outlined the criteria of the trials that were included.
    • This review reports the rates of adherence in the trials included.
    • This review reported the clinical outcomes in the trials included.
    • This review outlined the characteristics of studies with positive outcomes.
    • This review outlined the definition and measurement of adherence.

Review Of Included Controlled Clinical Trial Characteristics

  • Intervention – 12-week, group-based psychoeducation for patient and significant other.
    • Outcome – Medication adherence significantly better in intervention group. Decreased relapse rates, longer time to relapse and decreased manic symptoms.
  • Intervention – Facilitation intervention for psychiatric advance directives. Two-hour, semi- structured, manualized interview and guided discussion of choices for planning mental health care during future period of incapacity.
    • Outcome – Receiving at least one requested medication at the 12-month follow-up predicted greater adherence at 12 months. Shared decision-making could have significant impact on adherence.
  • Intervention – Seven sessions of individual psychoeducation or seven sessions psychoeducation plus 13 sessions cognitive behavior therapy (CBT). Psychoeducation based on a partial CBT model.
    • Outcome – No differences in medication adherence at 1 year. Those who received CBT plus psychoeducation experienced 50% fewer days of depressed mood over 1 year.
  • Intervention – 6-week, manualized group Life Goals Program with optional monthly group sessions.
    • Outcome – No statistical difference in adherence between the two groups. Statistically significant differences between groups at 12 months but fewer than half completed intervention.
  • Intervention – 12-week, group Medication Adherence Skills Training for patients >50 years of age.
    • Outcome – Percentage of patients reporting non-adherence declined by 15%.
  • Intervention – Twenty session cognitive therapy modified by addition of emotive techniques.
    • Outcome – At post-treatment 40.7% TAU and 60.0% intervention reported adequate compliance. At 12-month follow-up 66.7% TAU and 60% intervention reported adequate compliance. Few patients complied with blood tests for serum concentration levels. Differences in medication adherence not significant but intervention group trended to longer time to depressive relapse and improved dysfunctional attitudes.
  • Intervention – Manualized 21 session group psychoeducation.
    • Outcome – Mean serum levels for intervention relatively stable and always higher than mean baseline. Mean levels for TAU greater variability and were highest at baseline. Differences between serum levels was small.
  • Intervention – Individual manualized cognitive therapy, 12-18 sessions plus two maintenance.
    • Outcome – The cognitive therapy group was significantly more compliant with medication at 24 months and 30 months. Control medication only intervention. Significant correlation between self and key worker reports of compliance.
  • Intervention – Manualized Interpersonal and Social Rhythm Therapy (IPSRT).
    • Outcome – No difference in mood stabilizer serum levels following acute phase treatment. A two-phase trial that found participants who received IPSRT in the acute phase experienced longer time to new affective episode and more likely to remain well in 2-year maintenance phase.
  • Intervention – Manualized 9-month family-focused therapy.
    • Outcome – Patients receiving family-focused therapy had higher mean drug adherence scores. Analyses revealed no effect of drug adherence on depression scores at follow-up but those more adherent had lower mania scores. It was suggested that medication adherence mediated the effects of psychosocial interventions on mania symptoms but not depressive symptoms. Intervention group had longer relapse-free intervals during 2 years than control.
  • Intervention – Manualized 9-month family focused psychoeducational therapy or individualized supportive therapy.
    • Outcome – No significant differences between groups on medication compliance over 24-month period. The intervention reduced risk of relapse and rehospitalization. The differences in relapse and rehospitalization particularly significant at 12-month follow- up.

Conclusions

  • While only a few of the interventions reviewed improved adherence, most were associated with improved clinical outcomes.
    • This raised the question about the relationship of adherence to clinical to outcome. Further research needs to explore this relationship in more detail.
  • The studies demonstrating a positive outcome used psychoeducation, cognitive therapy, and family -focused therapy.

Clinical Implications

  • Rates of relapse in BD (even when taking prophylaxis) have been reported to be as high as 40% in the first year, 60% in the second year and 73% over 5 years or more.
  • Even though most studies in this analysis found that the described interventions did not improve adherence, they did improve clinical outcomes. This may be related to the context of adherence management, problems associated with calculating average adherence to multiple medications, and reliance on single measures of adherence. Consequently, it is suggested assessing adherence for each medication separately and combining adherence measurements. A Cochrane review of interventions to improve mediation adherence in long-term conditions found that the common component to successful interventions was more frequent interaction with patients with attention to adherence.

Disclosures

This summation has been developed independently of the authors. The authors reported no conflicts of interest.